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amin A/C Gene and the Heart
ow Genetics May Impact Clinical Care*
uisa Mestroni, MD, FACC, FESC,
atthew R. G. Taylor, MD, PHD
enver and Aurora, Colorado
amins are type V intermediate filament proteins that,
hanks to their tridimensional structure, are able to poly-
erize, forming an organized meshwork. The lamin poly-
ers lie between the inner nuclear membrane and the
hromatin and have a complex role in maintaining nuclear
hape and structure, transcriptional regulation, nuclear pore
ositioning and function, and heterochromatin organization
1). The lamin A/C gene (LMNA) produces two principal
soforms by alternative splicing, lamin A and C, which are
xpressed in a variety of terminally differentiated tissues;
herefore, LMNA mutations can cause multiple seemingly
isparate diseases including dilated cardiomyopathies
DCM) with conduction disease (CMD1A), the premature
ging syndrome Hutchinson’s progeria, skeletal myopathies
Emery-Dreifuss and limb-girdle muscular dystrophies),
harcot-Marie-Tooth type 2B1, familial partial lipodystro-
hy, restrictive dermopathy, and mandibuloacral dyspla-
ia, along with various overlapping phenotypes and rare
ariants (1,2).
See page 1250
The causative mechanisms for each phenotype remain the
ubject of ongoing studies and debates, but the most
mportant hypotheses are the nuclear fragility and disrup-
ion of the nuclear architecture, altered nuclear signaling,
nd finally, interference with the pre-lamin A processing
eading to nuclear accumulation of pre-lamin A (2).
ardiolaminopathy. Lamin A/C gene-related DCM is
haracterized by progressive heart failure, conduction dis-
ase, absent or variable skeletal muscle involvement, high
ortality rate, and high incidence of sudden death (3,4).
nalysis of the frequency of LMNA mutations in DCM
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uscular Dystrophy Association PN0007-056.opulations has been quite reproducible in several reports,
ccounting for 6% to 8% of DCM up to 9% in explanted
earts (3,5,6). The frequency reaches 30% in DCM with
onduction disease, particularly when skeletal muscle in-
olvement is present (7,8). In considering the clinical
elevance of the molecular genetics of LMNA, it is impor-
ant to evaluate its impact on prognosis and mortality (9). In
his regard, LMNA is not only the most frequent genes
ound in DCM, but also it has been shown to be associated
ith a very poor prognosis and high mortality rate.
In this issue of the Journal, Pasotti et al. (10) provide
urther insight into the LMNA–DCM phenotype in a
houghtful study analyzing the long-term outcome of 94
MNA mutation carriers belonging to 27 different DCM
amilies. Of these subjects, 60 showed an affected pheno-
ype, whereas 34 were clinically unaffected or showed only
inor cardiac abnormalities. During a median follow-up of
early 5 years, more than 70% of the affected subjects had an
dverse event. This adverse event was either progressive
ntractable heart failure causing death or need of transplant
n one-third of cases, whereas in as many as two-thirds, the
vent was a life-threatening arrhythmia. Although this study
ay be limited by the retrospective analysis, it remains signif-
cant for several reasons. First of all, the follow-up was
emarkably long, ranging from 3 to 9 years, and subjects were
egularly followed up clinically by the investigators. Second, the
esults of this investigation emphasize once more the severe
linical implications of LMNA mutations in DCM, and
articularly the high incidence of arrhythmia and sudden
eath. Interestingly, the investigators found a suggested link to
rior vigorous exercise and the risk of clinical events.
Similar findings were previously reported by other inves-
igators (3,4,5,11,12). Bécane et al. (11) first reported the
igh mortality and morbidity of LMNA in a large French
indred, in which almost 50% of affected relatives died
uddenly, whereas left ventricular dysfunction was seen to
apidly progress toward heart failure and heart transplant.
ur group found significant mortality and morbidity among
MNA carriers compared with other DCM patients in a
ohort of 49 nuclear families (40 with familial DCM and 9
ith sporadic DCM) that included 269 subjects, of whom
05 were affected. In this study, there was significant
henotypic variability, but the presence of skeletal muscle
nvolvement, supraventricular arrhythmia, and conduction
efects were predictors of LMNA mutations. Furthermore,
MNA mutation carriers had a significantly poorer survival
ompared with noncarrier DCM patients, with an event-
ree survival at the age of 45 years of 31% versus 75% for
oncarriers (3). Van Berlo et al. (12) pooled clinical data of
ll published carriers of LMNA mutations as a cause of
keletal and/or cardiac muscle disease. They found that
ardiac dysrhythmias and heart failure were common and
hat sudden death was the most frequently reported mode of
eath (46%) associated with both the cardiac and the
euromuscular phenotype. More recently, Meune et al. (4)
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Cardiolaminopathies and Clinical Care October 7, 2008:1261–2howed that 42% of their LMNA mutation carriers with an
mplantable cardioverter-defibrillator (ICD), during a
ollow-up of approximately 3 years, received appropriate
CD shocks for arrhythmia (ventricular fibrillation and
entricular tachycardia). Remarkably, left ventricular ejec-
ion fraction was not depressed in these patients, indicating
high risk of sudden death before the development of heart
ailure and significant myocardial dysfunction.
mpact of LMNA genetics on clinical care. Although for
CM patients with significant ventricular dysfunction con-
ensus guidelines address clinical decision making (9), one
f the challenges in the DCM field has been that molecular
iscoveries have far outpaced our knowledge of how to
linically manage affected patients and their relatives who
arbor mutations but have yet to manifest symptoms. For
he majority of DCM-related genes, data are quite limited
n terms of phenotypic predictors of a given DCM gene, the
rognosis of individual mutations, and how clinical man-
gement should change once a genetic mutation is detected.
espite these knowledge gaps, genetic testing for DCM has
ncreased rapidly, with at least 8 U.S.-based laboratories
ffering LMNA testing. A panel-based approach is evolving;
everal laboratories offer simultaneous testing of 6 to 10
CM genes, and larger panels are being developed. In the
ase of cardiolaminopathy, perhaps the most is known about
he clinical course and consequences of LMNA mutations,
nd already this information is influencing patient manage-
ent, at least at specialized centers. Pasotti et al. (10)
rovide additional data that LMNA mutations predict a
igh frequency of severe cardiac problems in symptomatic
atients. To be sure, this study reinforces the notion that
MNA patients with DCM are at very high risk for
rrhythmogenic complications and that early consideration
or defibrillator therapy is likely warranted in most cases.
he severity of LMNA mutations makes a compelling
rgument for offering genetic testing and/or echocardio-
raphic screening of at-risk relatives to identify other family
embers at risk of complications. Although the follow-up
ata in the study by Pasotti et al. (10) is too short to weigh
n on predictors of how and when overt disease develops in
symptomatic carriers, the investigators are well positioned
o report on this important question in a few more years.
It is interesting to note the apparent effect of prior vigorous
xercise as a predictor of clinical events, even though such
ctivities had been reduced an average of nearly 15 years before
CM diagnosis. The potential harm of exercise in asymptom-
tic LMNA carriers could be mentioned to interested patients,
ut we need more data before strong recommendations against
igorous exercise should be made. Although clinical cardiolo-
ists continue to become better educated in the genetics of
CM, genetic counseling and referral to a specialized center
xperienced in DCM testing and interpretation should prob-
bly still be offered to DCM patients and their families.
linical guidelines for the genetic evaluation of DCM and
ther cardiomyopathies are being developed to assist cardiol-
gists, who increasingly are recognizing these patients and
K
gust address the risks to currently healthy relatives as well as to
he individual affected patient.
onclusions
aken altogether, the study of Pasotti et al. (10) and the
revious studies discussed in the preceding text underscore the
linical severity of LMNA mutations and should prompt new
ore “personalized” guidelines for the clinical management of
atients with cardiolaminopathy. Probably to all patients with
CM, but certainly to all patients with DCM and conduction
isease, supraventricular arrhythmia or increased creatine ki-
ase level, genetic testing for the LMNA gene should be
ffered, because of the high risk of sudden death in these
atients, the possibility of prevention with ICD therapy, the
apid progression to intractable heart failure, and the need for
trict follow-up in consideration of heart transplant.
eprint requests and correspondence: Dr. Luisa Mestroni, Molec-
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venue, Aurora, Colorado 80045. E-mail: Luisa.Mestroni@
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